CNS Disorders & Pharmacology Module 3: CNS Depression

Instructor Details

  • Professor: Ben Roberts, MSN, CRNP, AGACNP-BC, ACHPN

  • Course Code: NURS 318

  • Term: Spring 2026

Objectives

  • By the end of this module, students will be able to:

    • Explain intentional CNS depression used to:

    1. Relieve pain

    2. Induce sleep

    3. Facilitate procedures

    4. Manage substance withdrawal

    • Distinguish types of opioid medications:

    • Agonists

    • Agonist–antagonists

    • Antagonists

    • Recognize and intervene in life-threatening CNS depression:

    • Respiratory arrest

    • Opioid overdose

    • Delirium tremens

    • Safely manage withdrawal syndromes related to alcohol, opioids, and nicotine

    • Prevent outcomes from dangerous drug combinations:

    • Opioids, benzodiazepines, alcohol

    • Prioritize nursing assessments, focusing on airway, breathing, and neurologic stability

Module 3 Overview

  • Focus:

    • Intentional suppression or modulation of CNS activity to:

    • Relieve pain

    • Induce sleep

    • Facilitate procedures

    • Manage substance withdrawal

    • High-risk use of medications that directly depress CNS function

  • NOT Focused on:

    • Mood stabilization or psychosis management (see CNS I)

    • Seizure prevention, Parkinson’s disease, or Alzheimer’s disease (see CNS II)

  • Clinical Level of Acuity:

    • High-acuity, often inpatient or emergent care

  • Emphasizes:

    • Respiratory depression and airway risk

    • Dangerous drug combinations (opioids, benzodiazepines, alcohol)

    • Withdrawal syndromes causing seizures, delirium, or death

  • Clinical Mindset:

    • “These drugs save lives and kill patients. My priority is airway, breathing, and rapid risk recognition.”

Block 1A: Pain Perception & Modulation

Understanding Pain and Its Modulation

  • Definition of Pain:

    • A subjective sensory and emotional experience caused by actual or potential tissue injury, influenced by both peripheral signals and central processing.

  • Key Pathophysiology:

    1. Peripheral nociception:

    • Tissue injury activates nociceptors which send pain signals via peripheral nerves to the spinal cord.

    1. Spinal transmission:

    • Pain signals ascend through the spinothalamic tract to the brain.

    1. Central perception:

    • The brain interprets pain based on context, emotion, prior experiences, and attention.

    1. Descending modulation:

    • CNS amplifies or dampens pain via inhibitory pathways (e.g., endogenous opioids, serotonin, norepinephrine).

  • Mechanism of Medication Efficacy:

    • Pain intensity is not determined solely by tissue damage; medications reduce pain by:

    • Blocking signal transmission

    • Enhancing inhibitory pathways

    • Altering central perception and response to pain

Block 1B: Opioid Analgesia & Risk Control

Understanding Opioid Analgesia

  • Definition:

    • Pharmacologic alteration of pain perception and response via CNS opioid receptors.

  • Key Pathophysiology:

    • μ-receptor activation:

    • Results in analgesia, euphoria, sedation, and respiratory depression.

    • κ-receptor activation:

    • Results in analgesia, sedation, and decreased gastrointestinal motility.

    • Physical dependence is expected with chronic exposure to opioids.

  • Mechanism of Action:

    • Opioids do not remove pain stimuli; they alter CNS interpretation and response to those stimuli.

Class: Opioid Agonists

  • Prototype: Morphine

  • Other Examples:

    • Oxycodone

    • Codeine

    • Hydromorphone

    • Fentanyl

  • Mechanism of Action (MOA):

    • Activates μ (primary) and κ opioid receptors, leading to analgesia, sedation, and respiratory depression.

  • Indications for Use:

    • Moderate to severe pain (post-operative, myocardial infarction, cancer)

    • Sedation

    • Cough suppression (codeine)

    • Decreased bowel motility (for diarrhea)

  • Adverse Effects (AEs):

    • Respiratory depression

    • Constipation

    • Orthostatic hypotension

    • Urinary retention

    • Sedation

    • Nausea/vomiting

  • Risks:

    • Respiratory rate (RR) < 12/min

    • Severe respiratory diseases

    • Renal failure (specific to meperidine)

    • Pregnancy and neonates

  • Drug-Drug Interactions (DDIs):

    • CNS Depressants:

    • Benzodiazepines, alcohol, barbiturates → additive CNS depression.

    • Tricyclic antidepressants (TCAs), antihistamines → increased anticholinergic effects.

    • Monoamine oxidase inhibitors (MAOIs) + meperidine → hyperpyrexic coma.

  • Nursing Considerations:

    • Hold opioid administration if RR < 12/min.

    • Have naloxone readily available at the bedside.

    • Implement a scheduled bowel regimen to prevent constipation.

    • Administer IV medications slowly.

    • Monitor patient-controlled analgesia (PCA) closely.

    • Fentanyl patch should be recognized for delayed onset (up to 24 hours).

Opioid Toxicity

  • Triad of Opioid Toxicity:

    • Coma

    • Respiratory depression

    • Pinpoint pupils

  • Management of Opioid Toxicity:

    • Provide airway support

    • Administer naloxone (often requires repeat dosing)

    • Continuous monitoring is essential due to opioid half-life exceeding that of naloxone.

Class: Opioid Antagonists

  • Prototype: Naloxone

  • Mechanism of Action (MOA):

    • Competes for opioid receptors to reverse opioid effects.

  • Indications for Use:

    • Opioid overdose

    • Neonatal respiratory depression

    • Opioid-induced constipation (for peripheral agents)

  • Adverse Effects (AEs):

    • Acute withdrawal syndrome

    • Hypertension

    • Tachycardia

    • Return of pain

  • Nursing Considerations:

    • Titrate naloxone to restore respiration but not to completely eliminate pain.

    • Repeat dosing is common, requiring monitoring for 2+ hours post-administration.

Block 1C: Adjuvant Medications for Pain

Purpose of Adjuvants

  • Functionality:

    • Enhance the effects of opioid analgesia which results in:

    • Decreased opioid dose required

    • Reduced risk of respiratory depression, sedation, and constipation

  • Clinical Pearl:

    • Adjuvant medications do not replace opioids; they complement their effect.

Classes of Adjuvant Medications

  1. Tricyclic Antidepressants (TCAs):

    • Example: Amitriptyline

    • Used for neuropathic pain

    • See CNS I for anticholinergic & cardiac toxicity

  2. Anticonvulsants:

    • Examples: Gabapentin, Carbamazepine

    • Used for neuropathic pain

    • See CNS II for Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN), complete blood counts (CBC), pregnancy risks

  3. CNS Stimulants:

    • Example: Methylphenidate

    • Counteracts the sedation from opioids

  4. Steroids:

    • Example: Dexamethasone

    • Decreases inflammation and increases appetite

  5. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs):

    • Example: Ibuprofen

    • Used for inflammatory pain

Block 2: Insomnia & Sedative-Hypnotics

Overview of Insomnia

  • Definition:

    • Difficulty in initiating or maintaining sleep, typically due to CNS hyperarousal or circadian disruption.

  • Key Pathophysiology:

    • Normal sleep requires a balance between arousal systems (histamine, norepinephrine (NE), dopamine, orexin), inhibitory signaling (via GABA), and circadian control (influenced by melatonin).

    • Insomnia results from:

    • Excessive arousal

    • Reduced inhibition

    • Misaligned circadian rhythm

  • Why Medications Work:

    • Sedative–hypnotics promote sleep by enhancing GABA inhibition or activating melatonin pathways.

    • They do not normalize sleep architecture and are associated with risks including cognitive impairment, respiratory suppression, falls, and dependence; hence their cautious and limited use is advocated.

Class: Nonbenzodiazepine Hypnotics (“Z-Drugs”)

  • Prototype: Zolpidem

  • Mechanism of Action (MOA):

    • Enhances GABA activity at specific benzodiazepine receptor subtypes to induce sleep.

    • Does NOT provide anxiolytic, muscle relaxant, or antiepileptic effects.

  • Indications:

    • Short-term management of insomnia

  • Adverse Effects (AEs):

    • Daytime sleepiness and lightheadedness

    • Headaches

    • Complex sleep behaviors (e.g., sleep driving, sleep eating)

    • Anterograde amnesia

    • Neonatal respiratory depression (if taken during pregnancy)

  • Contraindications / Precautions:

    • Pregnancy due to respiratory depression and withdrawal risks for neonates

    • Lactation: Safety is not established

    • Older adults

    • Renal, hepatic or respiratory impairment

  • Drug–Drug Interactions:

    • Additive CNS depression with opioids, alcohol, and other sedatives

  • Nursing Considerations:

    • Administer immediately before bedtime

    • Take on an empty stomach for faster absorption

    • Ensure ≥ 8 hours available for sleep time

    • Use only for short-term periods

    • Educate to stop medication and contact the provider if complex behaviors occur

Class: Melatonin Agonists

  • Prototype: Ramelteon

  • Mechanism of Action (MOA):

    • Activates melatonin receptors, thereby regulating circadian rhythms and promoting sleep onset.

  • Indications:

    • Chronic sleep-onset insomnia; permissible for long-term use

  • Adverse Effects (AEs):

    • Sleepiness, dizziness, fatigue

    • Hormonal effects: increased prolactin, decreased testosterone, amenorrhea, galactorrhea, infertility, decreased libido

  • Contraindications / Precautions:

    • Severe liver disease

    • Depression

    • Sleep apnea and Chronic Obstructive Pulmonary Disease (COPD)

    • Pregnancy: Use only if benefits outweigh risks

    • Lactation: Not recommended

    • Older adults should use cautiously

  • Drug–Drug / Drug–Food Interactions:

    • Concomitant use with fluvoxamine contraindicated due to increased ramelteon levels

    • High-fat meals delay absorption

    • Additive CNS depression with opioids and alcohol

  • Nursing Considerations:

    • Administer 30 minutes before bedtime

    • Take on an empty stomach and avoid high-fat foods

    • Not effective for sleep maintenance

    • Avoid hazardous activities if drowsy

    • Educate that this is a sleep-onset agent, not a sedative

Safety Considerations with Sedative-Hypnotics

  • Overview:

    • All sedative–hypnotics function as CNS depressants.

    • Combining these with opioids or alcohol can lead to respiratory arrest.

    • Benzodiazepines:

    • Dependence and withdrawal can result in life-threatening situations.

    • Z-drugs:

    • Complex sleep behaviors necessitate the cessation of medication.

    • Ramelteon:

    • Despite lacking dependence, hormonal effects should be monitored.

  • Nursing Priorities:

    • Focus on airway and breathing; continuous monitoring is critical.

    • Patient education is key to ensuring safety.

Block 3: IV Anesthetics & Procedural Sedation

Understanding Procedural Sedation

  • Definition:

    • Controlled, reversible CNS depression to facilitate procedures.

  • Key Pathophysiology:

    • Consciousness and pain perception depend on cortical processing, brainstem arousal, and autonomic control; IV sedatives depress that cortical and brainstem activity, suppressing respiration and airway reflexes, with a risk continuum extending from minimal sedation to general anesthesia.

    • Noteworthy: Small dosing errors can induce apnea, hypotension, or cardiac instability.

  • Mechanism of Drug Action:

    • IV anesthetics rapidly induce dose-dependent CNS suppression blocking pain and responsiveness while posing risk to vital functions; thus, continuous monitoring is essential.

Overview of IV Anesthetics

  • Intravenous Non-Opioid Agents:

    • Propofol

    • Ketamine

    • Barbiturates (e.g., pentobarbital, methohexital)

    • Benzodiazepines (e.g., midazolam, diazepam, lorazepam)

  • Intravenous Opioid Agents:

    • Fentanyl

    • Alfentanil, sufentanil

    • Morphine (in selected settings)

Key Agent-Specific Nursing Risks

  • Propofol:

    • Poses a risk for profound respiratory and cardiovascular depression.

    • Infection Risk: Opened vials must be used within 6 hours.

    • Hypotension is common after administration.

  • Ketamine:

    • May result in emergence reactions (hallucinations, agitation, confusion).

    • Avoid in clients with a history of mental illness; lower risk for emergence reactions seen in children <15 or adults >65 years.

    • Recommended recovery environment: quiet and low-stimulus.

    • Pre-medication with benzodiazepines may reduce adverse reactions.

  • Benzodiazepines (e.g., midazolam, diazepam):

    • Risk significant for respiratory depression.

    • Contraindicated in pregnancy and lactation.

    • Contraindicated in clients with glaucoma.

    • High risk of additive CNS depression exists.

  • Fentanyl:

    • Requires profound awareness of potential respiratory depression.

    • Can cause synergistic effects when combined with non-opioid sedatives.

Nursing Priorities during Procedural Sedation

  • Continuous monitoring of:

    • Respiratory rate

    • Oxygen saturation

    • Blood pressure

    • Electrocardiogram (ECG)

  • Readiness for airway management and resuscitation equipment

  • Ensuring mechanical ventilation readiness

  • Monitor throughout the procedure and post-procedure for delayed respiratory depression

  • Post-outpatient procedures:

    • Arrange an escort/ride home.

Block 4: Substance Withdrawal & Maintenance

Understanding Substance Dependence & Withdrawal

  • Definition:

    • Neuroadaptation resulting from repeated use of CNS-active substances leading to predictable withdrawal effects upon cessation.

  • Key Pathophysiology:

    • Chronic substance use alters receptors, neurotransmitter levels, and creates tolerance; stopping leads to autonomic hyperactivity, neurologic instability, and psychological distress.

    • Severity of withdrawal varies depending on the substance, dose, duration, and whether the drug is a CNS depressant or stimulant.

    • Alcohol and sedative–hypnotic withdrawal can be life-threatening; opioid withdrawal is generally non-fatal but highly distressing.

  • Mechanism of Medication Efficacy:

    • Medications stabilize CNS function through substitution, tapering, or controlling autonomic overactivity, with a focus on safety over rapid abstinence.

Alcohol Withdrawal

  • Timeline:

    • Onset: 4–12 hours after last intake.

    • Duration: 5–7 days.

    • Delirium tremens occurs 2–3 days after cessation, representing a medical emergency.

  • Manifestations:

    1. GI: Nausea, vomiting

    2. Neurologic: Tremors, seizures, hallucinations, illusions

    3. Autonomic: Diaphoresis, increased heart rate, increased blood pressure, increased respiratory rate, increased temperature

    4. Behavioral: Restlessness, insomnia, irritability

  • First-Line Treatment:

    • Benzodiazepines:

    • Chlordiazepoxide, Diazepam, Lorazepam

    • Intended Effects:

    • Maintain vital signs, reduce seizure risk, decrease severity of withdrawal manifestations.

  • Nursing Actions:

    • Obtain baseline vital signs

    • Monitor neurologic status and vital signs continuously

    • Implement seizure precautions

    • Administer scheduled or PRN doses as necessary

    • Antidote: Flumazenil for benzodiazepine toxicity

  • Adjunct Medications:

    • Carbamazepine: Decreases seizure risk

    • Clonidine: Decreases autonomic hyperactivity

    • Propranolol / Atenolol: Decreases heart rate, blood pressure, and cravings

    • Hold propranolol if HR < 60/min

Alcohol Abstinence Maintenance

  1. Disulfiram:

    • Functions as aversion therapy; ingestion of alcohol leads to acetaldehyde syndrome causing nausea/vomiting, hypotension, palpitations, weakness, potentially resulting in respiratory depression, seizures, or death.

    • RN Actions:

      • Monitor liver function tests and educate about strict avoidance of all alcohol sources (mouthwash, sauces, hand sanitizer).

      • Effects can persist 2 weeks post-discontinuation; a medical alert bracelet is suggested.

  2. Naltrexone:

    • Pure opioid antagonist sacrificing cravings and pleasurable effects of alcohol; also utilized for opioid use disorder.

    • RN Actions:

      • Verify the absence of opioid dependence and ensure clients abstain from alcohol before initiation.

      • Can be administered orally or as monthly intramuscular depot formulations.

  3. Acamprosate:

    • Alleviates dysphoria, anxiety, and restlessness during abstinence and is taken three times daily.

    • Teaching:

      • Diarrhea is common, so maintaining hydration is essential.

      • Avoid in pregnancy.

Opioid Withdrawal

  • Withdrawal Syndrome:

    • Onset: 1 hour to several days after last use.

  • Manifestations:

    • Agitation and insomnia

    • Flu-like symptoms

    • GI cramping and diarrhea

    • Piloerection, yawning, sweating

    • Note: Opioid withdrawal is generally not life-threatening, although suicide risk exists.

  • Methadone:

    • Oral opioid agonist that prevents withdrawal and cravings, transferring dependence to methadone.

    • RN Actions:

    • Dispense only through authorized programs; dosing titration is based on observed response; an eventual slow taper is necessary.

  • Buprenorphine:

    • Opioid agonist–antagonist that decreases cravings and withdrawal symptoms, exhibiting a safer respiratory profile than methadone.

    • RN Actions:

    • Can be prescribed by primary care providers; administration options include sublingual, buccal, or implant formulations (some may include naloxone).

  • Clonidine:

    • Reduces autonomic symptoms but does not alleviate cravings.

    • RN Actions:

    • Obtain baseline vital signs and monitor for hypotension.

    • Educate regarding dry mouth and sedation.

    • Antidote: Naloxone (detailed in the previous section).

Nicotine Withdrawal & Cessation

  • Withdrawal Manifestations:

    • Irritability

    • Restlessness

    • Insomnia

    • Difficulty concentrating

  • Bupropion:

    • Reduces nicotine cravings; contraindicated in clients with a risk of seizures.

  • Varenicline:

    • Partial nicotinic receptor agonist affecting cravings and relapse prevention.

    • RN Actions:

    • Monitor blood pressure, mood changes, depression, and suicidality; glycemic control should be observed in diabetic patients.

    • Occupational restrictions may apply (e.g., pilots, commercial drivers).

  • Nicotine Replacement Therapy (NRT):

    • Options include:

    • Lozenge

    • Gum

    • Patch (remove prior to MRI)

    • Nasal spray (advised against in cases with respiratory disease)

    • Inhaler

  • Key Teaching:

    • Avoid pregnancy/breastfeeding; do not combine NRT products; and be aware that e-cigarettes are not FDA-approved.

Block 5: Integrated Safety

Safety Principles Underlying the Module

  • Substance Withdrawal Safety Synthesis:

    • Alcohol withdrawal can be fatal.

    • Benzodiazepines are the first-line treatments for alcohol withdrawal.

    • Opioid withdrawal rarely leads to death but can present significant psychological risks.

    • Naloxone is effective for reversing opioids but not for alcohol or benzodiazepine overdoses.

    • Stability is prioritized over immediate abstinence in acute care.

    • Nursing priorities include:

    • Monitoring airway and vital signs

    • Assessing neurologic status

    • Evaluating possible suicide risk

  • Integrated Safety Map:

    • High-Risk Combinations:

    • Opioids + benzodiazepines + alcohol create a substantial risk for respiratory arrest due to sedative stacking leading to increased mortality.

    • Withdrawal Insights:

    • Alcohol withdrawal is dangerous and potentially fatal.

    • Benzodiazepines constitute the first-line treatment for alcohol withdrawal.

    • Opioid withdrawal poses lower mortality risk but carries high suicide risk.

    • Antidote limitations include:

    • Naloxone for opioid reversals but not for alcohol or benzodiazepines.

    • Flumazenil reverses benzodiazepines but may precipitate seizures.

  • Nursing Priorities:

    • Airway and breathing take precedence.

    • Continuous monitoring is essential, non-negotiable standard of care.

    • Stabilization is more important than quick abstinence in acute care contexts.

    • Clinical Anchor:

    • “These drugs save lives and can also kill patients. Nursing judgment is what makes the difference.”